The price of a Vertex cystic fibrosis treatment stirs anger in Australia

Stat News

23 April 2021 - The latest dustup over the cost of cystic fibrosis medicines sold by Vertex Pharmaceuticals is taking place in Australia, where an independent committee recommended that the government not cover a new combination treatment due to the cost and financial implications.

In explaining its decision, the PBAC acknowledged that the medicine, called Trikafta, provided a significant benefit for some patients, especially those with a particular gene mutation.

Read Stat News article

Michael Wonder

Posted by:

Michael Wonder